Last update March 19, 2020

Карбидопа

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

A peripheral inhibitor of the enzyme dopa-decarboxylase which transforms levodopa into dopamine.
Its only medical use is to associate it with levodopa in the treatment of Parkinson's disease in order to block the peripheral effects of levodopa by becoming dopamine (nausea, vomiting, arrhythmias) and allowing more levodopa to reach the brain and levodopa can be given at a lower dose.
Carbidopa does not cross the blood-brain barrier, so it has no effects at the level of the central nervous system.
Oral administration 3 to 4 times a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its wide volume of distribution and short half-life make it unlikely it will transfer into breastmilk in significant amounts.

Carbidopa increases prolactin levels (Masturzo 1979, Brown 1976) and inhibits the suppressive effects of levodopa on prolactin (Camanni 1978).


See below the information of this related product:

  • Levodopa (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for Карбидопа.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Карбидопа is Carbidopa in Cyrillic.

Is written in other languages:

Карбидопа is also known as

Group

Карбидопа belongs to this group or family:

Tradenames

Main tradenames from several countries containing Карбидопа in its composition:

List of 14 tradenames
  • Carlevod™. Contains other elements than Карбидопа in its composition
  • Cloison™. Contains other elements than Карбидопа in its composition
  • Credanil™. Contains other elements than Карбидопа in its composition
  • Duodopa™. Contains other elements than Карбидопа in its composition
  • Lebocar™. Contains other elements than Карбидопа in its composition
  • Lecarge™. Contains other elements than Карбидопа in its composition
  • Lodosyn™
  • Nakom™. Contains other elements than Карбидопа in its composition
  • Nervocur™. Contains other elements than Карбидопа in its composition
  • Parkinel™. Contains other elements than Карбидопа in its composition
  • Prikap™. Contains other elements than Карбидопа in its composition
  • Racovel™. Contains other elements than Карбидопа in its composition
  • Sinemet™. Contains other elements than Карбидопа in its composition
  • Ternovag™. Contains other elements than Карбидопа in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 58 %
Molecular weight 244 daltons
Protein Binding 76 %
VD 3.6 l/Kg
pKa 5.66 -
Tmax 2.4 hours
T½ 1.8 hours

References

  1. Merck. Levodopa/Carbidopa (Sinemet). Drug Summary. 2018 Full text (in our servers)
  2. AEMPS - MSD. Levodopa/Carbidopa (Sinemet). Ficha técnica. 2017 Full text (in our servers)
  3. Masturzo P, Murialdo G, Carolei A, Polleri A. Effects of the inhibition of aromatic aminoacids decarboxylase on prolactin secretion in humans. Boll Soc Ital Biol Sper. 1979 Feb 28;55(4):366-72. Abstract
  4. Camanni F, Picotti GB, Massara F, Molinatti GM, Mantegazza P, Müller EE. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients. J Clin Endocrinol Metab. 1978 Sep;47(3):647-52. Abstract
  5. Brown GM, Garfinkel PE, Warsh JJ, Stancer HC. Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man. J Clin Endocrinol Metab. 1976 Jul;43(1):236-9. Abstract

Total visits

1,270

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM